The FDA cleared an ultrasound-based infusion technology as a treatment for pulmonary embolism (PE). According to EKOS Corp., its EcoSonic system is the sole minimally invasive endovascular therapy on the market.

Physicians treating ischemic stroke one day may be able to determine patients’ risk for developing severe intracranial bleeding using an algorithm applied to standard MRI scans.

This week, two titans in transcatheter aortic valve replacement (TAVR) settled a feud over patents. One beneficiary of that agreement may be TAVR itself.

Tufts University announced today that Dariush Mozaffarian, M.D., Dr.P.H., has been named dean of the Gerald J. and Dorothy R.  Friedman School of Nutrition Science and Policy effective July 1. Mozaffarian joins the Friedman School from Harvard University, where he currently serves as associate professor and co-director of the Program in Cardiovascular Epidemiology at the Harvard School of Public Health (HSPH) and an associate professor in the Division of Cardiovascular Medicine at Harvard Medical School and Brigham and Women’s Hospital.

Further validating its advanced transcatheter aortic valve implantation (TAVI) technology, the Boston Scientific Corporation Lotus Valve System continued to demonstrate impressive performance at six months, according to new data presented at EuroPCR 2014 in Paris.

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today announced it has received approval for implementation of a Continuous Access Protocol (CAP) from the Food & Drug Administration (FDA) for RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella(R) RP (Right Peripheral) System.

Medtronic, Inc. today revealed new data showing that patients treated with the CoreValve System experienced positive clinical outcomes in the rigorous "real world" Medtronic CoreValve ADVANCE Study. Presented at EuroPCR 2014, the transcatheter aortic valve implantation (TAVI) study revealed low rates of mortality and stroke, and showed exceptional valve performance through two years.

Continuing its commitment to bringing advanced and clinically relevant interventional technologies to market, Medtronic, Inc. today announced CE (Conformité Européene) mark and launch of the NC Euphora(TM) Noncompliant Balloon Dilatation Catheter. The NC Euphora Balloon Catheter is now available in Europe and other countries outside of the United States that recognize the CE mark. It is not yet available in the United States.